Skip to main content
Premium Trial:

Request an Annual Quote

GenesisCare Takes Minority Stake in Precision Medicine Firm PreludeDx

NEW YORK — Australian cancer care provider GenesisCare said on Monday that it has taken a minority equity stake in PreludeDx, providing funds to help support the companies' recently announced breast cancer testing partnership.

Specific investment details were not disclosed.

Earlier this year, the firms signed an agreement under which PreludeDx's DCISionRT precision medicine test for women with breast cancer is being offered in Australia by GenesisCare. Patient access to the test is also being expanded in the US through GenesisCare's network of cancer centers.

The partners also agreed to work together to continue developing precision medicine tests for breast and other cancers, as well as to establish a global registry to evaluate DCISionRT's impact on treatment decision-making for women with ductal carcinoma in situ.

According to GenesisCare, the money it is providing to Laguna Hills, California-based PreludeDx through the equity investment will support the global data registry, expand the rollout of DCISionRT, and accelerate PreludeDx's development of a new early-stage breast cancer assay.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.